Figure 2.

The promiscuity of imatinib allows its application in multiple diseases. The structure of imatinib (from PDB 1IEP) is shown in the middle, with carbon (green), nitrogen (blue) and oxygen (red) atoms displayed. Shaded boxes indicate imatinib targets; blue shading indicates targets that are tyrosine kinases. CEL, chronic eosinophilic leukemia; CML, chronic myelogenous leukemia; GIST, gastrointestinal stromal tumors; KIT, receptor for stem cell factor; PDGFR, platelet-derived growth factor receptor; sMC, systemic mastocytosis; SSc, systemic sclerosis; V-ATPase, vacuolar ATPase.